Avadel Pharmaceuticals plc [AVDL] stock is trading at $8.33, down -0.72%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AVDL shares have gain 5.31% over the last week, with a monthly amount drifted -6.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $12. Previously, Rodman & Renshaw started tracking the stock with Buy rating on June 12, 2024, and set its price target to $27. On March 05, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $29 on the stock. Needham reiterated its Buy rating and increased its price target to $22 on March 05, 2024. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $25 on March 05, 2024. UBS started tracking with a Buy rating for this stock on February 06, 2024, and assigned it a price target of $21. In a note dated November 30, 2022, Jefferies upgraded an Buy rating on this stock and boosted its target price from $6.50 to $11.
Avadel Pharmaceuticals plc [AVDL] stock has fluctuated between $7.39 and $19.09 over the past year. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $8.33 at the most recent close of the market. An investor can expect a potential return of 180.07% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
Avadel Pharmaceuticals plc [NASDAQ:AVDL] reported sales of 169.12M for the trailing twelve months, which represents a growth of 159.14%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.25%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.66 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.25 points at the first support level, and at 8.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.45, and for the 2nd resistance point, it is at 8.57.
Ratios To Look Out For
For context, Avadel Pharmaceuticals plc’s Current Ratio is 2.75. Further, the Quick Ratio stands at 2.33, while the Cash Ratio is 1.05. Considering the valuation of this stock, the price to sales ratio is 4.76, the price to book ratio is 10.89.
Transactions by insiders
Recent insider trading involved Palczuk Linda, Director, that happened on Jan 21 ’25 when 5000.0 shares were purchased. Director, Thornton Peter J. completed a deal on Jan 13 ’25 to buy 10000.0 shares. Meanwhile, Director Ende Eric J bought 30000.0 shares on Jan 13 ’25.
